Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Assets (2016 - 2025)

RedHill Biopharma has reported Current Assets over the past 14 years, most recently at $6.5 million for Q4 2025.

  • Quarterly Current Assets fell 45.19% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, down 45.19% year-over-year, with the annual reading at $6.5 million for FY2025, 45.19% down from the prior year.
  • Current Assets was $6.5 million for Q4 2025 at RedHill Biopharma, down from $12.6 million in the prior quarter.
  • Over five years, Current Assets peaked at $98.5 million in Q2 2021 and troughed at $6.5 million in Q4 2025.
  • The 5-year median for Current Assets is $21.6 million (2023), against an average of $45.5 million.
  • Year-over-year, Current Assets soared 61.13% in 2021 and then crashed 81.21% in 2023.
  • A 5-year view of Current Assets shows it stood at $89.2 million in 2021, then fell by 3.65% to $85.9 million in 2022, then crashed by 81.21% to $16.1 million in 2023, then decreased by 26.2% to $11.9 million in 2024, then crashed by 45.19% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Current Assets are $6.5 million (Q4 2025), $12.6 million (Q2 2025), and $11.9 million (Q4 2024).